🇺🇸 Imipenem and Cilastatin Sodium in United States

198 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pneumonia — 25 reports (12.63%)
  2. Pyrexia — 25 reports (12.63%)
  3. Off Label Use — 22 reports (11.11%)
  4. Diarrhoea — 21 reports (10.61%)
  5. Platelet Count Decreased — 20 reports (10.1%)
  6. Anaemia — 19 reports (9.6%)
  7. Septic Shock — 18 reports (9.09%)
  8. Thrombocytopenia — 18 reports (9.09%)
  9. Rash — 15 reports (7.58%)
  10. Respiratory Failure — 15 reports (7.58%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Imipenem and Cilastatin Sodium approved in United States?

Imipenem and Cilastatin Sodium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Imipenem and Cilastatin Sodium in United States?

Jiangsu HengRui Medicine Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.